Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TOP2A | P11388 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8982725 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL6215994 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL8982958 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL8741055 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL8983061 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL6212519 | 0.94 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL6214793 | 0.89 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL9411083 | 0.88 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL9411046 | 0.88 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL6215997 | 0.88 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0550903-A1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1993-07-14 | — | — | EP | claimed |
| EP-3345594-B1 | SOLUBILIZED FLAVONOID COMPOSITION | TECH INVESTMENTS LC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210000958-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3345594-A1 | SOLUBILIZED FLAVONOID COMPOSITION | Vizuri Health Sciences LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2012054090-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS | API GENESIS, LLC (US) | 2012-04-26 | — | — | WO | disclosed |
| US-5480879-A | ANTIBACTERIAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-01-02 | — | — | US | disclosed |
| EP-0592868-A1 | Quinolonecarboxylic acids | BAYER AG (DE) | 1994-04-20 | — | — | EP | disclosed |
| EP-0591808-A1 | Quinolonecarboxylic acids | BAYER AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| EP-0550903-A1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1993-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | KDM4E 2079/4885ALDH1A1 1920/4885HPGD 244/4885 |
| US-20210000958-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | KDM4E 2079/4885ALDH1A1 1920/4885HPGD 244/4885 |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | KDM4E 2079/4885ALDH1A1 1920/4885HPGD 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.